Repeated TRPA1 Blockade Reduces Nociception and Neuroinflammation in a Relapsing–Remitting Mouse Model of Multiple Sclerosis
Authors:
- Ana Clara Machado LuizAna Clara Machado Luiz
- Diulle Spat PeresDiulle Spat Peres
- Sabrina Qader KudsiSabrina Qader Kudsi
- Ricardo Iuri Felix MoraesRicardo Iuri Felix Moraes
- Caren AntoniazziCaren Antoniazzi
- Leonardo Gomes PereiraLeonardo Gomes Pereira
- Helen Alves BritoHelen Alves Brito
- Micheli Mainardi PillatMicheli Mainardi Pillat
- Mariana Martins FloresMariana Martins Flores
- Patrícia RodriguesPatrícia Rodrigues
- Gabriela TrevisanGabriela Trevisan
Open Access
- 27 October 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9592
Abstract
Relapsing–remitting multiple sclerosis (RRMS) is a chronic autoimmune and neurodegenerative disease characterized by neuroinflammation and demyelination. Neuropathic pain is a frequent and poorly managed symptom associated with oxidative stress. Transient receptor potential ankyrin 1 (TRPA1), which is activated by oxidative mediators, contributes to nociceptive signaling and neuroinflammatory processes in the relapsing–remitting experimental autoimmune encephalomyelitis (RR-EAE) model. This study investigated the effects of repeated pharmacological blockade of TRPA1 on nociceptive behaviors and disease-associated pathological mechanisms using an RR-EAE mouse model. Female C57BL/6 mice received the TRPA1 antagonist A-967079 (30 mg/kg, intragastric) from day 16 to day 36 post-induction. Behavioral, molecular, and biochemical analyses were performed. Repeated administration of A-967079 attenuated mechanical and cold allodynia without impairing locomotor function or altering body weight. TRPA1 antagonism modulated glial marker expression and plasma pro-inflammatory cytokine levels. A-967079 attenuated oxidative stress, reducing hydrogen peroxide, 4-hydroxynonenal, advanced oxidation protein product levels (TRPA1 endogenous agonists), and NADPH–cytochrome c reductase activity. These findings demonstrate that repeated TRPA1 antagonism effectively modulates neuropathic pain-like behaviors and targets key pathological mechanisms associated with RRMS. This approach closely reflects clinical management, as treatment was initiated after disease onset, when symptoms were already present. Our results support TRPA1 antagonism as a promising therapeutic strategy for pain management in RRMS.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (#303485/2026-4)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (402536/2024-0)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (#173401/2023-6)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (#88887.002501/2024-00)
This publication has 50 references indexed in Scilit:
- Characterization of Depression- and Anxiety-Like Behaviours in a Mouse Model of Relapsing-Remitting Multiple SclerosisJournal of Neuroimmune Pharmacology, 2023
- Advances in the Understanding and Management of Chronic Pain in Multiple Sclerosis: a Comprehensive ReviewCurrent Pain and Headache Reports, 2019
- Transient receptor potential ankyrin 1 (TRPA1) plays a critical role in a mouse model of cancer painInternational Journal of Cancer, 2018
- Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitisJournal of Neuroscience Research, 2018
- Systematic assessment and characterization of chronic pain in multiple sclerosis patientsNeurological Sciences, 2017
- The TRPA1 Channel in Inflammatory and Neuropathic Pain and Migraine2014
- Transient Receptor Potential Ankyrin 1 Receptor Stimulation by Hydrogen Peroxide Is Critical to Trigger Pain During Monosodium Urate–Induced Inflammation in RodentsArthritis & Rheumatism, 2013
- A mechanism-based classification of pain in multiple sclerosisJournal of Neurology, 2012
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: A comparative studyGlia, 1999